Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Target

BCMA×CD3

1 product

83 abstracts

Abstract
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
Org: Karmanos Cancer Institute, Ziekenhuis Netwerk Antwerpen Stuivenberg, Regeneron Pharmaceuticals, Inc.,
Abstract
First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Org: Sackler School of Medicine, Hospital Universitario Fundación Jiménez Díaz, McGill University and MUHC, Sungkyunkwan University School of Medicine, Hospital Germans Trias i Pujol,
Abstract
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
Org: Weill Cornell Medical College - New York Presbyterian Hospital, Fox Chase Cancer Center, Arnie Charbonneau Cancer Institute, University of Calgary, Massachusetts General Hospital Cancer Center, Pfizer SLU,
Abstract
Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.
Org: Saint-Louis Hospital, APHP, University Paris Cité, Paris and Saint Cloud, France,
Abstract
A potential best-in-class BCMA-CD19 bispecific CART with advanced safety by self-inhibiting IFNG signaling during CRS.
Org: Celledit, The Third Affiliated Hospital of Southern Medical University, The First Affiliated Hospital of University of Science and Technology of China, The Second Xiangya Hospital of Central South University,
Abstract
Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis.
Org: University of Alabama at Birmingham, University Medical Center Hamburg-Eppendorf, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Vrije Universiteit Amsterdam, Stanford University School of Medicine,
Abstract
MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
Org: Pfizer Oncology Division,
Abstract
Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Org: Froedtert & Medical College of Wisconsin Cancer Center, Tulane Cancer Center, Tulane University Schoool of Medicine, Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus Dresden,
Abstract
Evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38–directed therapy: MagnetisMM-32.
Org: UCHealth Cancer Care and Hematology, Department of Hematology, Yamagata University Hospital,
Abstract
Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).
Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Karmanos Cancer Institute, University of Miami Health System,
Abstract
Long-term follow-up of ARI0002h (cesnicabtagene autoleucel), an academic point-of-care B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell strategy: Activity and safety after fractionated initial therapy and booster dose in 60 patients with relapsed/refractory multiple myeloma (RRMM).
Org: IMIB-Pascual Parrilla, University of Murcia, Complutense University, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Biomedicina de Sevilla (IBIS)/CSIC,
Abstract
OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Org: Denver, CO, Colorado Blood Cancer Institute, Eugene, OR, Janssen US Oncology Medical Affairs, Janssen Scientific Affairs LLC,
Abstract
Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.
Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Mayo Clinic Rochester, Rochester, MN, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Org: Froedtert & Medical College of Wisconsin Cancer Center, Tulane Cancer Center, Tulane University Schoool of Medicine, Universitätsklinikum Carl Gustav Carus Dresden,
Abstract
Combination of pirtobrutinib and lentiviral transduced bispecific anti-CD20/CD19 (LV20.19) CAR T-cell therapy to improve outcomes in patients with relapsed/refractory lymphoma.
Org: Medical College of Wisconsin Center for AIDS Intervention Research, Medical College of Wisconsin, Division of Hematology & Oncology,
Abstract
Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup.
Org: Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center,
Abstract
Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma.
Org: Horsham, PA,
Abstract
Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9.
Org: Japanese Red Cross Medical Center, St. David's South Austin Medical Center,
Abstract
Exposure-response analyses for optimal therapeutic dose selection of ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM).
Org: Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Froedtert & Medical College of Wisconsin Cancer Center,
Abstract
Evaluation of a novel method to guide belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire.
Org: Health Data Specialists,
Abstract
Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma.
Org: Yale School of Public Health, Yale University Shool of Medicine,
Abstract
Association of patient (pt) factors and pharmacodynamic biomarkers with progression-free survival (PFS) after idecabtagene vicleucel (ide-cel) in pts from KarMMa-3.
Org: Hospital Clinico Universitario de Salamanca,
Abstract
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.
Org: Royal Marsden Hospital NHS Foundation Trust, Medical Oncology Service, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), National and Kapodistrian University of Athens,
Abstract
BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement.
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, H. Lee Moffitt Cancer Center and Research Institute, University of Pennsylvania, Hospital of the University of Pennsylvania, University of California, San Francisco,
Abstract
Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL).
Org: The Ohio State University, Division of Hematology, The Ohio State University, Department of Internal Medicine, The Ohio State University, College of Medicine,
Abstract
Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).
Org: Hopital Bretonneau,
Abstract
Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3.
Org: Bristol Myers Squibb, Mayo Clinic, Lille University Hospital, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Preferences among patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) in the era of B-cell maturation antigen (BCMA)-directed T-cell–engaging therapies.
Org: Mayo Clinic Florida, Regeneron Pharmaceuticals, Inc., RTI Health Solutions,
Abstract
Class comparison of BCMA-directed therapies in relapsed multiple myeloma.
Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Rochester, MN, Mayo Clinic Florida, Jacksonville, FL,
Abstract
CD19/BCMA dual-targeting FasTCAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin lymphoma: An update.
Org: Gracell Biotechnologies Ltd., Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.
Org: University College London Cancer Institute, University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Medical College of Wisconsin, Peter MacCallum Cancer Centre, Melbourne, Australia, Hematology Clinic,
Abstract
Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).
Org: Gracell Biotechnologies Ltd,
Abstract
Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).
Org: University of Chicago, Novartis Institutes for BioMedical Research, Medical College of Wisconsin, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center,
Abstract
MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma.
Org: Salamanca University Hospital, Department of Hematology and Cancer Prevention, Medical University of Silesia, Katowice, Poland, Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Pfizer Inc., Paris, France, Pfizer Inc., Cambridge, MA,
Abstract
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
Org: Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute/Tennessee Oncology, UPMC Hillman Cancer Center, Abramson Cancer Center, Karmanos Cancer Institute,
Abstract
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.
Org: State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated With Shanghai Jiao Tong University School of Medicine, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,
Abstract
Treatment patterns for extramedullary multiple myeloma and outcomes with CAR-T therapy and bispecific antibodies.
Org: Mayo Clinic, Mayo Clinic (Rochester, MN), Mayo Clinic Department of Pediatric and Adolescent Medicine, Division of Hematology, Mayo Clinic, Rochester, MN,
Abstract
Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.
Org: Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Gracell Biotechnologies Ltd., Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma.
Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
Population pharmacokinetic-pharmacodynamic model of nirogacestat effects on B-cell maturation antigen in healthy subjects.
Org: SpringWorks Therapeutics, SpringWorksTherapeutics, ICON BioAnalytical Laboratories, Nuventra Pharma Sciences,
Abstract
Identification of cytokines associated with response and cytokine release syndrome: Analysis of MagnetisMM-3 cohort A.
Org: Arnie Charbonneau Cancer Institute, University of Calgary, University of Calgary, Clinica Universidad de Navarra, Pfizer SLU, Pfizer Oncology Division,
Product
TMZ
Abstract
Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).
Org: Medical College of Wisconsin, Milwaukee, Froedtert & Medical College of Wisconsin, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, University of Arkansas Medical Sciences,
Abstract
Patient perspectives on BCMA-targeted therapies for multiple myeloma: A survey conducted in a patient advocacy group.
Org: HealthTree Foundation, Janssen Scientific Affairs, Janssen Global Services, LLC, Janssen US Oncology Medical Affairs, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT,
Abstract
Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM).
Org: Bristol Myers Squibb, Princeton, NJ, Massachusetts General Hospital, Boston, MA, MD Anderson Cancer Center,
Abstract
MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Org: Centre Hospitalier Universitaire de Nantes, Clinica São Germano, São Paulo, Brazil, Columbia University Medical Center, Sylvester Comprehensive Cancer Center, Miami, FL, Janssen Research & Development,
Abstract
Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study.
Org: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece, Health Data Specialists, Dublin, Ireland, Dublin, Ireland, Alexandra Hospital, Athens, Greece,
Abstract
Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
Org: Memorial Sloan Kettering Cancer Center, MSKCC, Myeloma Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Adult Bone Marrow Transplant Service,
Abstract
MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
Org: Department of Hematology and Cancer Prevention, Medical University of Silesia, Katowice, Poland, China Medical University Hospital, Taichung, Taiwan, Division of Hematology, National Taiwan University Hospital, Taipei, Taiwan, Seoul National University Hospital, Seoul, South Korea, Pfizer Inc., New York, NY, Pfizer SLU, Madrid, Spain,
Abstract
Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Org: Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Vrije Universiteit Amsterdam, Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Levine Cancer Institute/Atrium Health, Charlotte, NC,
Abstract
Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
Org: Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, MD Anderson Cancer Center, Houston, TX, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, Division of Hematologic Malignancies and Cellular Therapeutics (HMCT), University of Kansas Medical Center, Kansas City, KS, Virginia Commonwealth University Massey Cancer Center, Richmond, VA, Levine Cancer Institute, Charlotte, NC, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic, Phoenix, AZ, Dana-Farber Cancer Institute, Palm Beach, FL, Dana-Farber Cancer Institute, Boston, MA, H. Lee Moffitt Cancer Center, Tampa, FL, City of Hope Comprehensive Cancer Center, Duarte, CA, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, City of Hope Comprehensive Cancer Center, Durante, CA, Mayo Clinic, Rochester, MN, Stanford University School of Medicine, Stanford, CA,
Abstract
Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.
Org: Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Vrije Universiteit Amsterdam, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania,
Abstract
Prognostic value of month 1 bone marrow and PET MRD status in CAR-T therapy for myeloma.
Org: Division of Hematology, Mayo Clinic, Rochester, MN, Department of Radiology, Mayo Clinic, Rochester, MN, Mayo Clinic, Rochester, MN, Division of Medical Oncology, Mayo Clinic, Rochester, MN, Mayo Clinic, Phoenix, AZ, Mayo Clinic Florida, Jacksonville, FL,
Abstract
Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.
Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, CHU de Poitiers, Hôpital de la Milétrie - Centre Hospitalier Universitaire de Poitiers, Pôle Régional de Cancérologie,
Abstract
Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs).
Org: Bristol Myers Squibb, Princeton Health, Lille University Hospital, Lille, France, Mayo Clinic,
Abstract
A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).
Org: Sarah Cannon Research Institute/Tennessee Oncology, Department of Hematology, University of California San Francisco, Icahn School of Medicine, Mount Sinai, Onc/Hem Care Inc, Center for Discovery and Innovation, Hackensack Meridian Health,
Abstract
An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM).
Org: University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Bethanien Hospital, Erasmus University Medical Center, Statlog,
Abstract
Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.
Org: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Chinese Academy of Medical Science & Peking Union Medical Co,
Abstract
Crossing the US-Mexico border for cancer care: Which treatments are more sought-after?
Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, University of North Carolina at Chapel Hill, Vanderbilt University Medical Center, ISSSTE CMN 20 De Noviembre, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico,
Abstract
Association of frailty and high-risk immuno-nutritional score with outcomes in patients with relapsed and refractory multiple myeloma treated with chimeric antigen receptor T-cells.
Org: H. Lee Moffitt Cancer Center and Research Institute, Senior Adult Oncology Program, Moffitt Cancer Center, Supportive Care Program, Department of Malignant Hematology,
Abstract
Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1.
Org: Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada, Moores Cancer Center, University of California San Diego, La Jolla, CA, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Department of Medical Oncology, Baylor Scott and White Health, Dallas, TX,
Abstract
Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
Org: Sorbonne University and Saint-Antoine Hospital, Hôpital Saint-Antoine, INSERM UMRs938, Holden Comprehensive Cancer Center, University of Iowa Hospitals & Clinics,
Abstract
CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.
Org: Mayo Clinic, Sarah Cannon Transplant and Cellular Therapy Program, Genentech, F. Hoffmann-La Roche Ltd,
Abstract
Quality assessment of information on chimeric antigen receptor T-cell therapy on YouTube: An analysis.
Org: Government Medical College and Hospital, Chandigarh, India, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, University of Vermont Medical Center; Division of Hematology-Oncology, Burlington, VT, New York Presbyterian Queens, Flushing, NY, Institute of Liver and Biliary Sciences, Delhi, India,
Abstract
Hypophosphatemia and thrombocytopenia: A retrospective chart review to identify markers for prediction of CRS and ICANS in CAR T-cell therapy.
Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Arizona, Tucson, AZ, University of Arizona Cancer Center, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital,
Abstract
Comprehensive myeloid-derived suppressor cell (MDSC) immunophenotyping and functional assessment in chimeric antigen receptor (CAR) T therapy.
Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Medical Center, Duke University Cancer Institute,
Abstract
Early detection of CRS after CAR-T therapy using wearable monitoring devices: Preliminary results in relapsed/refractory multiple myeloma (RRMM).
Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Current Health, Dorset County Hospital, NHS Foundation Trust, Tisch Cancer Institute, Mount Sinai School of Medicine,
Abstract
Association of venetoclax-based therapy with increased survival in multiple myeloma (MM) harboring t(11;14): A single-center experience.
Org: H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine,
Abstract
Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies.
Org: Massachusetts College of Pharmacy and Health Sciences, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Division of Hematology and Oncology,
Abstract
Characterizing outcomes in severe cytopenias by 3 months in BCMA and CD19 CAR-T cell therapies: A single institution experience.
Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Emory University School of Medicine, Biostatistics Shared Resource, Emory University, Atlanta, GA, USA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,
Abstract
CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: Updated results of phase 1b/2 study (FUMANBA-1).
Org: Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science, Wuhan, China, Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University and the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Department of Hematology, The First Affliated Hospital, Zhejiang University;, Hangzhou, China, Jiangsu Province Hospital, Nanjing, China, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China,
Abstract
Rural communities and health professional shortage areas (HPSA) and access to immune effector cellular therapy and lymphoma/myeloma clinical trials.
Org: The University of Kansas Medical Center, University of Kansas Medical Center, Department of Biostatistics & Data Science, The University of Kansas Cancer Center, US Myeloma Research Innovations Research Collaborative (USMIRC), University of Kansas Medical Center Department of Internal Medicine,
Abstract
Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT).
Org: The University of Kansas Medical Center, Levine Cancer Institute, Mitchell Cancer Institute, UT Southwestern Medical Center, University of Kansas Cancer Center, Kansas City, KS,
Abstract
Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study.
Org: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece, Health Data Specialists, Dublin, Ireland, Dublin, Ireland, Alexandra Hospital, Athens, Greece, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece, Health Data Specialists, Dublin, Ireland, Alexandra Hospital, Athens, Greece,
Abstract
Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update.
Org: Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY, Washington University, St. Louis, MO, Hematology Department, University Hospital of Leon, Leon, Spain, Catholic University of Leuven, Leuven, Belgium,
Abstract
Marketing approvals for cell and gene therapy products in oncology: Current review of EMA and FDA approvals.
Org: Parexel, Uxbridge, Durham Veteran Affairs Medical Center, NC Medical Research, Matica Biotechnology,
Abstract
Cytology-histology correlation, time to diagnosis and time to therapy when cytology is performed in addition to biopsies in malignant spinal lesions of previously unknown malignant disease.
Org: Department of Oncology, Haematology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Department of Orthopedics and Trauma Surgery, Section for Spine Surgery, University Hospital Hamburg Eppendorf, Hamburg, Germany, Institute of Pathology, University Hospital Hamburg Eppendorf, Hamburg, Germany, RKH Orthopädische Klinik Markgröningen gGmbH, Markgröningen, Germany, Department of Orthopedics and Trauma Surgery, University Hospital Hamburg Eppendorf, Hamburg, Germany,
Abstract
Adverse events during chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies (HM): Real-world, US patient experience.
Org: EVERSANA, Burlington, ON, Canada, Milwaukee, Wigen Biomedicine Technology (Shanghai), Bangalore Medical College And Research Institute, Indiana University – Purdue University Indianapolis,
Abstract
Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3.
Org: UCLA Medical Center, Santa Monica, CA, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada, Baylor University Medical Center, Dallas, TX, Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite, France, Fox Chase Cancer Center, Philadelphia, PA,
Abstract
Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies.
Org: EVERSANA, Burlington, ON, Canada, Milwaukee, Wigen Biomedicine Technology (Shanghai), Yardley, PainReform,
Abstract
Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment.
Org: Vanderbilt University Medical Center, Hematology Department, Hospital Universitari i Politècnic La Fe, CHU Nantes-Department of Hepato-Gastroenterology, University of North Carolina School of Medicine, University of Wisconsin Health,
Abstract
Racial disparities and inequity in clinical trials of chimeric antigen receptor T-cell therapy.
Org: Jacobi Medical Center/NYCHHC, Jacobi Medical Center/Albert Einstein College of Medicine, MedStar Union Memorial Hospital, Rochester Regional Hospital, Jacobi Medical Center/North Central Bronx,
Abstract
Clinical outcomes of patients with multiple myeloma following disease progression after BCMA-targeted CAR T-cell therapy.
Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, UT Health Sciences Center at Houston, University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study.
Org: Cerner Enviza, Pfizer Inc., London, United Kingdom,